Company intelligence / Profile preview
MAS Life Science
- Ownership
- Private
- Employees
- ~20
- Development stage
- Other
Overview
MAS Life Science is a South Korean biotechnology company focused on developing small molecule therapeutics for metabolic and aging-related diseases. Their lead program, MAS-101, targets mitochondrial dysfunction to treat nonalcoholic steatohepatitis (NASH) and liver fibrosis. The company utilizes a proprietary platform to identify mitochondrial modulators that regulate energy metabolism and cellular health.
- Therapeutic areas
- EndocrinologyGastroenterologyMetabolic Disorders
- Modalities
- Small molecule
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on MAS Life Science.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MAS Life Science.